

47.(amended) A pharmaceutical composition comprising  
an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, or an  
HLA binding fragment thereof and  
a pharmaceutically acceptable carrier.

53.(amended) The pharmaceutical composition of claim[s] 47[-52], further comprising an  
adjuvant.

60.(amended) An expression vector comprising an isolated nucleic acid molecule of [any of]  
claims 54[-59] operably linked to a promoter.

68.(amended) An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 54  
[or claim 55].

101.(amended) A method for treating a condition characterized by expression in a subject  
of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1  
nucleic acid molecule, comprising  
administering to a subject a pharmaceutical composition of any one of claims [13-25 and  
37-] 15, 41 and 47 in an amount effective to prevent, delay the onset of, or inhibit the condition  
in the subject.

113.(amended) A composition of matter useful in stimulating an immune response to a  
plurality of [a] proteins encoded by nucleic acid molecules that are NA Group 1 molecules,  
comprising  
a plurality of peptides derived from the amino acid sequences of the proteins, wherein the  
peptides bind to one or more MHC molecules presented on the surface of the cells which express  
an abnormal amount of the protein.